Azatadine
Optimine, Trinalin (azatadine) is a small molecule pharmaceutical. Azatadine was first approved as Optimine on 1982-01-01. It is used to treat allergic rhinitis perennial, allergic rhinitis seasonal, ear diseases, respiration disorders, and urticaria in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Azatadine maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OPTIMINE | Merck & Co | N-017601 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Azatadine maleate
+
Pseudoephedrine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRINALIN | Merck & Co | N-018506 DISCN | 1982-03-23 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Azatadine |
| INN | azatadine |
| Description | Azatadine is a benzo[5,6]cyclohepta[1,2-b]pyridine having a 1-methylpiperidin-4-ylidene group at the 11-position. It has a role as a H1-receptor antagonist and an anti-allergic agent. It is a benzocycloheptapyridine and a tertiary amine. |
| Classification | Small molecule |
| Drug class | tricyclic histaminic-H1 receptor antagonists, loratadine derivatives (formerly-tadine) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 3964-81-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL946 |
| ChEBI ID | 2946 |
| PubChem CID | 19861 |
| DrugBank | DB00719 |
| UNII ID | 94Z39NID6C (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Azatadine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Azatadine
+
Pseudoephedrine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 97 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use